Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Share-based Compensation: 2011-2024

Historic Share-based Compensation for OptimizeRx (OPRX) over the last 14 years, with FY2024 value amounting to $11.5 million.

  • OptimizeRx's Share-based Compensation fell 2488.48% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 4322.31%. This contributed to the annual value of $11.5 million for FY2024, which is 1640.3% down from last year.
  • According to the latest figures from FY2024, OptimizeRx's Share-based Compensation is $11.5 million, which was down 1640.3% from $13.7 million recorded in FY2023.
  • OptimizeRx's Share-based Compensation's 5-year high stood at $15.7 million during FY2022, with a 5-year trough of $3.2 million in FY2020.
  • Its 5-year average for Share-based Compensation is $9.9 million, with a median of $11.5 million in 2024.
  • In the last 5 years, OptimizeRx's Share-based Compensation skyrocketed by 18670.69% in 2022 and then plummeted by 1640.3% in 2024.
  • OptimizeRx's Share-based Compensation (Annual) stood at $3.2 million in 2020, then surged by 73.09% to $5.5 million in 2021, then surged by 186.71% to $15.7 million in 2022, then decreased by 12.88% to $13.7 million in 2023, then decreased by 16.4% to $11.5 million in 2024.
  • Its Share-based Compensation stands at $11.5 million for FY2024, versus $13.7 million for FY2023 and $15.7 million for FY2022.